Concord Biotech, a company in the Pharmaceuticals industry, reported revenue of ₹312 crore and net profit of ₹76 crore for the September 2026 quarter.
Concord Biotech (NSE: CONCORDBIO) closed at ₹548.20 on 20 Nov 2026, down 23.9% over the past year. Its market capitalisation is ₹11,470 crore and it trades at 38.6 times earnings.
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.